Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Rafferty Asset Management LLC

Rafferty Asset Management LLC lessened its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGXFree Report) by 52.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 167,795 shares of the company’s stock after selling 182,486 shares during the period. Rafferty Asset Management LLC’s holdings in Protagonist Therapeutics were worth $3,848,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently made changes to their positions in PTGX. State Board of Administration of Florida Retirement System boosted its position in shares of Protagonist Therapeutics by 5.9% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 16,303 shares of the company’s stock valued at $272,000 after purchasing an additional 910 shares during the period. Principal Financial Group Inc. lifted its stake in Protagonist Therapeutics by 7.7% in the third quarter. Principal Financial Group Inc. now owns 14,971 shares of the company’s stock valued at $250,000 after buying an additional 1,068 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Protagonist Therapeutics by 11.8% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,338 shares of the company’s stock valued at $237,000 after buying an additional 1,093 shares during the last quarter. FMR LLC boosted its holdings in shares of Protagonist Therapeutics by 0.4% in the third quarter. FMR LLC now owns 509,242 shares of the company’s stock valued at $8,494,000 after acquiring an additional 1,835 shares during the period. Finally, Swiss National Bank grew its position in shares of Protagonist Therapeutics by 2.7% during the third quarter. Swiss National Bank now owns 100,600 shares of the company’s stock worth $1,678,000 after acquiring an additional 2,600 shares during the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on PTGX shares. StockNews.com upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 28th. HC Wainwright reissued a “buy” rating and set a $38.00 price target on shares of Protagonist Therapeutics in a report on Thursday, May 9th. JPMorgan Chase & Co. upped their price objective on Protagonist Therapeutics from $34.00 to $37.00 and gave the company an “overweight” rating in a research note on Wednesday, February 28th. Finally, JMP Securities lifted their target price on Protagonist Therapeutics from $42.00 to $45.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 8th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Protagonist Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $38.00.

Get Our Latest Report on Protagonist Therapeutics

Protagonist Therapeutics Trading Up 2.3 %

NASDAQ:PTGX opened at $34.80 on Friday. Protagonist Therapeutics, Inc. has a 12-month low of $13.72 and a 12-month high of $35.55. The firm has a market cap of $2.04 billion, a price-to-earnings ratio of 14.26 and a beta of 2.12. The company’s 50-day moving average is $28.32 and its two-hundred day moving average is $26.13.

Protagonist Therapeutics (NASDAQ:PTGXGet Free Report) last announced its earnings results on Tuesday, May 7th. The company reported $3.26 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.51 by $0.75. The firm had revenue of $254.95 million for the quarter, compared to analyst estimates of $300.00 million. On average, equities research analysts forecast that Protagonist Therapeutics, Inc. will post 1.67 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Asif Ali sold 1,234 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $25.11, for a total transaction of $30,985.74. Following the transaction, the chief financial officer now directly owns 37,163 shares in the company, valued at approximately $933,162.93. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, CFO Asif Ali sold 1,234 shares of the company’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $25.11, for a total transaction of $30,985.74. Following the completion of the sale, the chief financial officer now directly owns 37,163 shares in the company, valued at approximately $933,162.93. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Dinesh V. Ph D. Patel sold 25,000 shares of Protagonist Therapeutics stock in a transaction on Monday, April 1st. The shares were sold at an average price of $28.31, for a total value of $707,750.00. Following the completion of the transaction, the chief executive officer now owns 549,590 shares in the company, valued at approximately $15,558,892.90. The disclosure for this sale can be found here. Company insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Profile

(Free Report)

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.

Featured Stories

Want to see what other hedge funds are holding PTGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Protagonist Therapeutics, Inc. (NASDAQ:PTGXFree Report).

Institutional Ownership by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.